Subject: Digital ILC 2020 Viral Hepatitis track revealed
From: EASL Office <[email-masked]>
To: [email-masked]
Date: Thu, 23 Jul 2020 09:29:20 +0000

What is the latest in viral hepatitis research?

23 July 2020

Read online

World Hepatitis Day is around the corner, taking place next Tuesday, 28 July. EASL is part of the worldwide action plan calling for elimination of viral hepatitis as a global public health threat by 2030. Hence, Digital ILC 2020 will provide a platform for leading experts to discuss the remaining obstacles to HCV elimination and review the upcoming treatments and new insights for other forms of viral hepatitis.

Digital ILC 2020 preview:

Highlights in Hepatitis B and D drug development

What is the latest in viral hepatitis research? What developments are in the pipeline for Hepatitis B and D?

To find out how this area of research is evolving, watch this video, “Highlights in Hepatitis B and D drug development” presented by the session Co-Chair, Dr Markus Cornberg.

The Digital ILC 2020 Viral Hepatitis track provides updates on the progress towards HCV elimination and highlights the latest breakthroughs in finding a cure for Hepatitis B.

The sessions will provide a detailed overview and latest science on topics such as:

Hepatitis B and D - Translational  and drug development

Hepatitis C - Therapy and resistance, long-term management, post-SVR and long-term follow up as well as elimination

Hepatitis E - From virology to treatment

Hepatitis: Immunology

And more...

Throughout the event, you can attend a wide range of sessions to learn and interact with 9,000+ members of the hepatology community.

Click on the images below to discover the content for each type of session.

Meet the experts session

"Meet the experts" is an ideal opportunity for you to learn from some of the biggest names in hepatology and to meet them in an engaging and interactive setting!

See all "Meet the experts" sessions

Zoom on a session

HEV - From virology to treatment

Hepatitis E virus is one of the most common causes of acute hepatitis and jaundice in the world. In addition, HEV can cause diverse neurological as well as other extrahepatic manifestations, and trigger acute-on-chronic liver failure in patients with pre-existing cirrhosis.

This interactive session will provide a state-of-the-art update on Hepatitis E, including an overview on current hot topics in this area, the molecular virology and pathogenesis of hepatitis E, as well as the prevention and treatment of HEV infection. Key points will include:

providing a primer on the epidemiology, clinical manifestations, diagnosis, and management of acute and chronic hepatitis E

highlighting advances in research on the HEV life cycle and the identification of targets for antiviral intervention

discussing the immune response to HEV as well as determinants of infection outcome and

providing an overview of current and emerging preventive as well as therapeutic strategies.

Browse the scientific programme of

The Digital ILC 2020

Our carefully curated selection of original live and on-demand content brings you a congress programme of unprecedented global relevance, reach, and convenience. Whether you are in the Americas, Africa, Asia, Europe, or Oceania, all the key presentations and much more will be just a click away.

Register now for The Digital ILC 2020

We trust that this glimpse of key sessions dedicated to Viral Hepatitis has convinced you to register for The Digital ILC 2020.

The Digital ILC 2020 is the key event for you to learn, share, and interact with some of the greatest names in hepatology. In addition, the event showcases the latest in science and the most important updates in liver disease management. All these at a global level, thanks to:

159 chairs from 18 countries

Abstracts submitter authors from 50 countries

Abstract presenters from 56 countries

98 sessions

Over 100 hours of video content

Faculty diversity: 88 women and 125 men

Very special registration rates are now available, starting at 100 euros.

I would like to register

Do you need more reasons to register?

Here are our top 7 reasons to attend the Digital ILC 2020:

100+ hours of cutting-edge scientific content

all the scientific content will only be available to registered participants

registration includes the exclusive access to the full on-demand content until 31 December 2020

dedicated session on COVID-19 and the liver

scientific programme with global reach and relevance

digital platform with high interactivity, close to onsite experience

wide range of sessions with engaging scientific and educational content

Prepare for The Digital ILC 2020

Selected articles from the Journal of Hepatology:

Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B

Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial

Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection

EASL Clinical Practice Guidelines on hepatitis E virus infection

Selected resources from EASL Campus

On EASL Campus, discover over 530 dedicated resources on Viral Hepatitis.

(Re)discover the “Best of ILC 2019” Slide Deck

Selected EASL resources

Hepatitis C virus (HCV) infection is a major cause of chronic liver disease. As a result, in 2018, worldwide there were approximately 71 million chronically infected individuals.

EASL Recommendations on Treatment of Hepatitis C describe the optimal management of patients with acute and chronic HCV infections in 2018 and onwards.

Read EASL’s Recommendations on Treatment of HCV

Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. Most importantly, all patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC).

Therefore, the EASL Guidelines for Hepatitis B present updated recommendations for the optimal management of HBV infection.

Read EASL’s Guidelines for HBV

Download the EASL app

Access event info, EASL Campus and stay informed with the latest messages and news.

For the latest news on The Digital ILC 2020, follow the official #ILC2020 on Twitter

@EASLnews and @EASLedu

Share with a friend or colleague

EASL’s mission is supported by an unrestricted education grant from Abbvie and Bristol-Myers Squibb.

EASL, The Home of Hepatology

7 rue Daubin, 1203 Geneva, Switzerland

+41 22 807 03 60

www.easl.eu

[email-masked]

Update your preferences or unsubscribe